Hunts Point is on the east side of Lake Washington.
![slomo ride slomo ride](https://i.ytimg.com/vi/LjJUHtZtlfo/maxresdefault.jpg)
In 1949, Sayres built a 17-room home on the east side of Hunts Point near the point's north end (4450 Hunts Point Road), along with a boathouse for his hydroplanes. He became interested in speedboat racing in 1926 in Oregon, and his interest continued after he moved to King County, Washington. Sayres also owned the Jen-Cel-Lite Corporation, a manufacturer of cold weather clothes. He was in the automobile business heading the American Automobile Company, a Chrysler car dealership at 1001 Broadway in Seattle, and an auto parts store in the University District.
Slomo ride driver#
Sayres (1896-1956), the owner and driver of the hydroplane, moved to King County in 1932. With Sayres, Seattle automobile dealer and sportsman at the wheel, Ted Jones, Boeing supervisor and designer of the craft in the bucket seat alongside, Slo-mo-shun IV made the first run over the measured mile in 21.98 seconds or 163.785 miles per hour, the second one in 22.95 seconds or 157.2 miles per hour ( Seattle P-I, June 27, 1950). Naval Air Station, Sand Point, on Lake Washington. Stan Sayres' amazing hydroplane, Seattle designed and Seattle built, Monday established a new world speed mark when it averaged 160.3235 miles per hour in two dashes over a measured mile off U. The Seattle Post-Intelligencer announced the world record run with: The run on Lake Washington is completed about 7:10 a.m., so early that few people witness the event. His speed of 160.3235 mph betters the previous record of 141 mph set in 1939 in England. To read this article on click here.On June 26, 1950, in Lake Washington, the hydroplane Slo-mo-shun IV, piloted by Stan Sayres (1896-1956), shatters the world speed record on water.
Slomo ride download#
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.īe sure to follow all of these stock-moving metrics, and many more, on. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. This group has a Zacks Industry Rank of 213, putting it in the bottom 17% of all 250+ industries. The Medical - Biomedical and Genetics industry is part of the Medical sector. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.38 based on yesterday's closing prices. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. We can also see that MRNA currently has a PEG ratio of 0.68. Its industry sports an average Forward P/E of 24.39, so we one might conclude that MRNA is trading at a discount comparatively. Valuation is also important, so investors should note that MRNA has a Forward P/E ratio of 8.16 right now. MRNA is currently sporting a Zacks Rank of #3 (Hold). Within the past 30 days, our consensus EPS projection remained stagnant. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988.
![slomo ride slomo ride](https://i.ytimg.com/vi/mzOagkHzP9Y/maxresdefault.jpg)
Our system takes these estimate changes into account and delivers a clear, actionable rating model. We developed the Zacks Rank to capitalize on this phenomenon. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.īased on our research, we believe these estimate revisions are directly related to near-team stock moves.
![slomo ride slomo ride](https://i.ytimg.com/vi/wjC1fy0u_w8/maxresdefault.jpg)
These revisions help to show the ever-changing nature of near-term business trends. Investors might also notice recent changes to analyst estimates for MRNA.